04:18 PM EDT, 05/12/2026 (MT Newswires) -- Capricor Therapeutics ( CAPR ) reported late Tuesday a Q1 net loss of $0.59 per diluted share, widening from a loss of $0.53 a year earlier.
Analysts polled by FactSet expected a loss of $0.51.
The company said its cash balance of about $279 million is expected to support operations through Q4 of 2027.